Post Profile






First-line pembrolizumab plus chemotherapy improves outcomes in advanced NSCLC

(European Society for Medical Oncology) The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers reported at the ESMO 2016 Congress in Copenhagen today.
read more

share

Related Posts


Multimodality Treatment for Metastatic Lung Cancer That Includes Surgery May Improve Survival Rates

Health : Newswise Medical News

Patients diagnosed with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection (removal of all or part of the lung) in combination with chemotherapy and radiation therapy

Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, rese...

Precision Therapeutics' ChemoFx® Demonstrates Significant Role In Selection Of Chemotherapy Doublets In Non Small Cell Lung Cancer

Health : Medical News Today

Drs. Rodney Landreneau and Matthew Schuchert from the University of Pittsburgh presented a new non small cell lung cancer study at the 2011 Society of Surgical Oncology (SSO) conference in San Antonio, Texas. Dr. Landreneau is Direc...

Merck KGaA: Survival In 1st-Line Non-Small Cell Lung Cancer (NSCLC) Significantly Prolonged By Erbitux(R)

Health : Medical News Today

Data presented today at the 1st International Thoracic Oncology Congress Dresden (ITOCD) demonstrate that the addition of Erbitux® (cetuximab) to standard platinum-based chemotherapy in the 1st-line treatment of advanced NSCLC resul...

First-line pembrolizumab plus chemotherapy significantly improves outcomes in advanced NSCLC

Diseases & Conditions / Cancer : ScienceDaily: Cancer

The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers report.

Comments


Copyright © 2016 Regator, LLC